The Oncology Institute, Inc.
TOI
$0.716
$0.09114.56%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 22.29% | 23.31% | 25.30% | 28.42% | 32.79% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 22.29% | 23.31% | 25.30% | 28.42% | 32.79% |
| Cost of Revenue | 30.57% | 30.11% | 29.88% | 32.08% | 32.08% |
| Gross Profit | -11.65% | -4.31% | 6.63% | 14.36% | 35.77% |
| SG&A Expenses | -4.11% | -5.75% | -4.74% | -3.98% | -14.98% |
| Depreciation & Amortization | 12.19% | 27.58% | 29.83% | 33.14% | 32.59% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.45% | 18.14% | 17.87% | 18.87% | 12.59% |
| Operating Income | -4.93% | 4.54% | 11.18% | 15.15% | 36.68% |
| Income Before Tax | 6.45% | -17.91% | -47.52% | -91,223.08% | -5,523.42% |
| Income Tax Expenses | -252.81% | 27.82% | 78.89% | 85.19% | 96.20% |
| Earnings from Continuing Operations | 6.75% | -18.10% | -48.50% | -54,750.00% | -7,609.57% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 6.75% | -18.10% | -48.50% | -54,750.00% | -7,609.57% |
| EBIT | -4.93% | 4.54% | 11.18% | 15.15% | 36.68% |
| EBITDA | -4.21% | 7.11% | 14.13% | 18.35% | 39.81% |
| EPS Basic | 7.47% | -18.04% | -48.15% | -28,048.48% | -4,667.43% |
| Normalized Basic EPS | -27.87% | -60.15% | -63.02% | -35.89% | 30.84% |
| EPS Diluted | 14.93% | 11.35% | -6.03% | -308.44% | -448.81% |
| Normalized Diluted EPS | -27.87% | -62.19% | -65.10% | -39.53% | 29.71% |
| Average Basic Shares Outstanding | 1.43% | 1.17% | 1.34% | 1.14% | 1.87% |
| Average Diluted Shares Outstanding | 1.43% | -1.33% | -1.17% | -2.34% | -1.67% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
